Abstract
HIV-1 Gag p24 has long been identified as an informative biomarker of HIV replication, disease progression and therapeutic efficacy, but the lower sensitivity of immunoassays in comparison to molecular tests and the interference with antibodies in chronic HIV infection limits its application for clinical monitoring. The development of ultrasensitive protein detection technologies may help overcoming these limitations. Here we evaluated whether immune-complex dissociation combined with ultrasensitive digital ELISA Simoa technology could be used to quantify p24 in plasma samples from people with HIV-1 infection. We found that, among different immune-complex dissociation methods, only acid-mediated dissociation was compatible with ultrasensitive p24 quantification by digital ELISA, strongly enhancing p24 detection at different stages of HIV-1 infection. We show that ultrasensitive p24 levels correlated positively with plasma HIV-RNA and HIV-DNA and negatively with CD4+ T cells in the samples from people with primary and chronic HIV-1 infection. In addition, p24 levels also correlated with plasma D-dimers and IFNα levels. P24 levels sharply decreased to undetectable levels after initiation of combined antiretroviral treatment (cART). However, we identified a group of people who, 48 weeks after cART initiation, had detectable p24 levels despite having undetectable viral loads. These people had different virologic and immunologic baseline characteristics when compared with people who had undetectable p24 after cART. These results demonstrate that ultrasensitive p24 analysis provides an efficient and robust mean to monitor p24 antigen in plasma samples from people with HIV-1 infection, including during antiretroviral treatment, and may provide complementary information to other commonly used biomarkers.
Importance The introduction of combined antiretroviral treatment has transformed HIV-1 infection in a manageable condition. In this context, there is a need for additional biomarkers to monitor HIV-1 residual disease or the outcome of new interventions, such as in the case of HIV cure strategies. The p24 antigen has a long half-live outside viral particles and it is therefore a very promising marker to monitor episodes of viral replication or transient activation of the viral reservoir. However, the formation of immune-complexes with anti-p24 antibodies difficult its quantification beyond acute HIV-1 infection. We show here that, upon immune-complex dissociation, new technologies allow the ultrasensitive p24 quantification in plasma samples throughout HIV-1 infection, at levels close to that of viral RNA and DNA determinations. Our results further indicate that ultrasensitive p24 quantification may have added value when used in combination with other classic clinical biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the ANRS, the French National Agency of research on AIDS and Viral Hepatitis and by MSDAvenir to A.S.‐C. This study was developed in the context of the ANRS RHIVIERA program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Blood samples from HIV‐negative controls were obtained from the French Blood Bank (Etablissement Francais du Sang) in the context of a collaboration agreement with the Institut Pasteur (C CPSL UNT, number 15/EFS/023). Plasma samples from people with acute and chronic HIV‐1 infection monitored for virologic markers at the Hospital Necker‐Enfants malades (France) were used to determine the efficacy of ICD and the sensitivity of the Quanterix Simoa p24 assay in plasma samples. Plasma samples from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO6 PRIMO cohort (NCT03148964) and ANRS 12180 Reflate TB trial (NCT02273765) were used to validate the protocol for ultrasensitive p24 detection combined with ICD. ANRS PRIMO cohort was approved by the Ile‐de‐France‐3 Ethics Committee and all patients give their written informed consent. The ANRS 12180 Reflate TB trial was carried out in accordance with the ANRS Ethical Chart for Research in Developing Countries, the Brazilian regulatory requirements for clinical trials and the Declaration of Helsinki. The protocol was approved by national and local ethics committees in Brazil (Comissao Nacional de Etica em Pesquisa [CONEP] and Comite de Etica em Pesquisa [CEP] at IPEC/FIOCRUZ) and France (Comite de Protection des Personnes de Paris Ile‐de‐France‐I). The experiments were conducted with the understanding and the written informed consent of each participant
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available in the manuscript or upon request. No datasets were generated
